Recruiting Trials

The following research trials are currently open to patients with peripheral nerve diseases in the UK.

This list is not yet complete. See also https://clinicaltrials.gov/ which is the international registry of all clinical trials, searchable by disease and country, which also provides further technical information.

Most clinical trials will pay reasonable travel expenses for patients to attend the hospital. You will have to attend the hospital for monitoring visits which may be quite frequent.  

Disease

Name of trial

Intervention

Inclusion criteria

Locations

General information

Contact

CIDP

Advance-CIDP-1

Hyqvia – subcutaneous immunoglobulin with hyaluronidase, which allows faster higher-volume infusion by softening the subcutaneous tissues.  Generally it has fewer side effects than IVIG, infusion as fast as IVIG without iv cannulation. There is a 50% chance of getting placebo

Already on regular IVIG every 2-6 weeks.

May be most attractive to patients with adverse effects from IVIG, or poor venous access, or who would like to switch to subcutaneous treatment but are on a high dose (eg average >80g/month) which makes conventional subcutaneous Ig less attractive (due to multiple needles and/or frequent treatment). 

Exclusion criteria - pure sensory CIDP, IgM paraprotein, MAG Antibodies, diabetic neuropathy or HbA1c>7.5%,  immunosuppressive drugs in the past 6 months, prednisolone>10mg/d, or patients without clear therapeutic benefit from IVIG. 

 

London (King’s SE5 9RS), Liverpool, Bristol

This combines many of the advantages of IVIG and subcutaneous immunoglobulin - it is a subcutaneous product which can be infused at the same speed and dosing frequency as IVIG (typically once every 2-4 weeks through a single needle), but avoiding intravenous cannulation, and avoiding the peak-dose adverse effects of IVIG.

 

The protocol to stop IVIG suddenly, then start either Hyqvia or placebo infusions. If you worsen, you will be assessed, then may go back on IVIG.  https://clinicaltrials.gov/ct2/show/NCT02549170

020 3299 7142 Juel Tuazon